Table 2.
Values of regression variables used to estimate utility, probability of test uptake and maximally tolerated rate of severe ADR for patients to prefer testing. Data are taken from source, or derived according to standard epidemiological calculations
| Attributes | Expected probabilities conditional on AED and HLA-A*31:01 test result | Testing strategy | Reference | |||
|---|---|---|---|---|---|---|
| CBZ/-ve | CBZ/+ve | LTG/+ve | Test | No test | ||
| Remission | 36.000 | 36.000 | 29.000 | 35.8189 | 36.0000 | 1 |
| Fewer seizures | 17.370 | 17.370 | 21.430 | 17.4751 | 17.3700 | 1 |
| Memory problems | 3.1746 | 3.1746 | 2.6455 | 3.1609 | 3.1746 | 1 |
| Skin rash | 7.000 | 34.000 | 4.000 | 6.9224 | 7.6986 | 1,7 |
| Severe ADR | 0.0738 | 1.0895 | 0.0354 | 0.0728 | 0.1001 | 7,15,17 |
All data are reported as number of events per 100 patients.
AED, anti-epileptic drug; CBZ, carbamazepine; LTG, lamotrigine; ADR, adverse drug reaction.